2026
May
Yin and Yang of tumoral NK cells: cytotoxic and suppressive phenotypes uncovered
May 19, 2026
NK cells are promising targets for cancer immunotherapy, but clinical results have so far been limited. Therefore, there is a need to better understand NK cell subphenotypes and their function in tumors. Two recent papers characterized tumoral NK cells. In Cancer Immunology Research, Lozada et al. characterized proinflammatory and suppressive NK cells across...
Intratumoral anti-CTLA-4 could reduce severe AEs: Results from a phase 1b clinical trial
May 13, 2026
The combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), both administered intravenously, has been approved for the treatment of cancer in a variety of settings since 2015, but its use is frequently hindered by severe adverse events, more often associated with the use of anti-CTLA-4. In an effort to reduce this toxicity, Tselikas and...
NK cells unleashed by Treg ablation
May 6, 2026
When tumors lose expression of MHC-I under the selective pressure of CD8+ T cells, NK cells may step in and take on a more prominent antitumor role, but often this is still insufficient to control tumors. Investigating potential mechanisms limiting NK cell antitumor activity, Zhang et al. found that Tregs have a strong...
